November 9, 2017 / 1:06 PM / a month ago

BRIEF-Redhill Biopharma says last patient enrolled in Phase III study with RHB-104 for Crohn’s disease

Nov 9 (Reuters) - Redhill Biopharma Ltd

* Redhill Biopharma announces last patient enrolled in the Phase III study with RHB-104 for Crohn’s disease

* Redhill Biopharma Ltd - ‍top-line results are expected to be announced in mid-2018​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below